|Bid||13.28 x 39400|
|Ask||13.29 x 41800|
|Day's Range||13.07 - 13.34|
|52 Week Range||5.48 - 14.42|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||0.04 (0.30%)|
|Ex-Dividend Date||Mar 05, 2021|
|1y Target Est||14.46|
General Electric (GE) closed the most recent trading day at $13.21, making no change from the previous trading session.
GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer.
Crane's (CR) Q1 results improve year over year on the back of solid sales and margin performance. It raises projections for 2021, anticipating strengthening end-market businesses.